1.54
Medicinova Inc stock is traded at $1.54, with a volume of 67,845.
It is up +1.99% in the last 24 hours and down -1.91% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.51
Open:
$1.49
24h Volume:
67,845
Relative Volume:
0.08
Market Cap:
$75.69M
Revenue:
$134.60K
Net Income/Loss:
$-11.81M
P/E Ratio:
-6.3927
EPS:
-0.2409
Net Cash Flow:
$-10.05M
1W Performance:
-1.28%
1M Performance:
-1.91%
6M Performance:
+11.59%
1Y Performance:
-28.04%
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MNOV
Medicinova Inc
|
1.54 | 74.21M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - MSN
Stocks of Medicinova Inc (MNOV) are poised to climb above their peers - Setenews
Is MediciNova Inc. stock attractive for growth ETFsPortfolio Gains Summary & Risk Controlled Swing Alerts - BỘ NỘI VỤ
Why MediciNova Inc. stock could benefit from AI revolutionWeekly Gains Summary & Entry Point Strategy Guides - moha.gov.vn
Market Moves: Why MediciNova Inc. stock could benefit from AI revolutionAnalyst Downgrade & Verified Entry Point Signals - BỘ NỘI VỤ
MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Can MediciNova Inc. stock attract ESG capital inflowsPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Can MediciNova Inc. stock beat market expectations this quarterCPI Data & Weekly Breakout Stock Alerts - newser.com
Will MediciNova Inc. stock continue upward momentumJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Trend analysis for MediciNova Inc. this weekJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
Will MediciNova Inc. stock maintain growth story2025 Top Decliners & Daily Profit Focused Screening - newser.com
What Fibonacci levels say about MediciNova Inc. reboundWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
What dividend safety score for MediciNova Inc. stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Is MediciNova Inc. stock a contrarian buy2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Applying big data sentiment scoring on MediciNova Inc.2025 Key Highlights & Smart Swing Trading Alerts - newser.com
MediciNova appoints former FDA official as clinical advisor By Investing.com - Investing.com Nigeria
MediciNova appoints former FDA official as clinical advisor - Investing.com
MediciNova, Inc. Appoints Dr. Christopher D. Breder as Clinical and Regulatory Advisor - Quiver Quantitative
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):